Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Mesylate

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    229 result(s) found for: Mesylate. Displaying page 1 of 12.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2016-001894-34 Sponsor Protocol Number: E7389-A001-113 Start Date*: 2016-11-16
    Sponsor Name:Eisai Inc.
    Full Title: A Phase 1 Study of Eribulin Mesylate (E7389, IND #116,292), a Novel Microtubule Targeting Chemotherapeutic Agent in Children with Refractory or Recurrent Solid Tumors (Excluding CNS), Including Lym...
    Medical condition: Solid Tumors including Lymphomas
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-001432-13 Sponsor Protocol Number: MRZ 92579/TI/3004 Start Date*: 2008-10-20
    Sponsor Name:Merz Pharmaceuticals GmbH
    Full Title: An Open-Label, Long-Term Treatment Study to assess the Long-Term Safety and Tolerability and Efficacy of Neramexane in Patients with Subjective Tinnitus
    Medical condition: Long-term safety, tolerability and efficacy of Neramexane in Patients with subjective Tinnitus.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10042398 Subjective tinnitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) AT (Prematurely Ended) NL (Prematurely Ended) DE (Prematurely Ended) GB (Prematurely Ended) BE (Completed) FR (Completed) PT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-001592-36 Sponsor Protocol Number: MRZ 92579 – 0508/1 Start Date*: 2005-09-30
    Sponsor Name:Merz Pharmaceuticals GmbH
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Clinical Dose-Ranging Trial to Evaluate Efficacy and Safety of a NMDA antagonist for Oral Administration in Patients with Subjective Tinnitus
    Medical condition: Subjective Tinnitus
    Disease: Version SOC Term Classification Code Term Level
    8.1 10042398 Subjective tinnitus LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-000639-16 Sponsor Protocol Number: MRZ 92579-TI/3002 Start Date*: 2008-10-03
    Sponsor Name:Merz Pharmaceuticals GmbH
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Clinical Evaluation of the Efficacy, Safety and Tolerability of Neramexane in Patients with Subjective Tinnitus
    Medical condition: Efficacy, Safety and Tolerability of Neramexane in Patients with Subjective Tinnitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10042398 Subjective tinnitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) NL (Completed) FR (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-011246-25 Sponsor Protocol Number: MRZ 92579/TI/3003 Start Date*: 2009-11-04
    Sponsor Name:Merz Pharmaceuticals GmbH
    Full Title: MRZ 92579/TI/3003: A Randomized, Double-Blind, Placebo-Controlled, Clinical Evaluation of the Efficacy, Safety and Tolerability of Neramexane in Patients with Subjective Tinnitus
    Medical condition: Subjective Tinnitus
    Disease: Version SOC Term Classification Code Term Level
    13.1 10013993 - Ear and labyrinth disorders 10042398 Subjective tinnitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-002520-18 Sponsor Protocol Number: MRZ 92579 – 0405/1 Start Date*: 2005-03-15
    Sponsor Name:Merz Pharmaceuticals GmbH
    Full Title: Safety and efficacy of Neramexane mesylate as add-on therapy to opioids in cancer patients for the management of chronic pain attributable to skeletal metastases: A randomised, double-blind, placeb...
    Medical condition: Moderate to severe chronic pain (cancer pain)
    Disease: Version SOC Term Classification Code Term Level
    7.1 10058019 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-004998-83 Sponsor Protocol Number: MUS92579_2057_1 Start Date*: 2012-04-04
    Sponsor Name:Merz Pharmaceuticals GmbH
    Full Title: A Double-Blind, Randomized, Dose Selection Vehicle–Controlled Multicenter Clinical Study for Evaluation of the Safety, Tolerability, Efficacy, and Pharmacokinetics of topical Neramexane in Subjects...
    Medical condition: Moderate to severe acne
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004858 10000497 Acnes HLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-004063-29 Sponsor Protocol Number: CSTI571BDE40 Start Date*: 2004-12-21
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Glivec (imatinib mesylate) in combination with hydroxyurea or hydroxyurea alone as an oral therapy in temozolomide resistant progressive glioblastoma patients
    Medical condition: Glioblastoma multiforme/astrocytoma WHO grade IV, with progression on temozolomide containing regimen
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-001782-18 Sponsor Protocol Number: MRZ 92579-0404/1 Start Date*: 2005-02-14
    Sponsor Name:Merz Pharmaceuticals GmbH
    Full Title: Saftey and efficacy of two different doses of Neramexane mesylate as preemptive analgesic and add-on therapy to opioids in the management of postoperative pain. A randomised, double-blind, placebo-...
    Medical condition: Moderate to severe acute postoperative pain
    Disease: Version SOC Term Classification Code Term Level
    7.1 10054711 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2007-006119-22 Sponsor Protocol Number: FARM6HJ7CA Start Date*: 2008-03-25
    Sponsor Name:UNIVERSITA' DEGLI STUDI DI NAPOLI FEDERICO II
    Full Title: Phase II monitored clinical trial for evaluation of treatment of patients with Thymic Epithelial Tumours (TET) or Histiocitosi X (LCH) with Imatinib Mesylate.
    Medical condition: Patients affected by TET or LCH
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-002165-20 Sponsor Protocol Number: 20040110 Start Date*: 2005-02-18
    Sponsor Name:Amgen Inc
    Full Title: An open label study of AMG 706 in subjects with advanced gastrointestinal stromal tumors (GISTs) who developed progressive disease or relapsed while on Imatinib Mesylate.
    Medical condition: Gastrointestinal stromal tumour (GIST)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-001251-41 Sponsor Protocol Number: P20/05 Start Date*: 2020-04-17
    Sponsor Name:CH de Versailles
    Full Title: A PROOF OF CONCEPT STUDY TESTING THE VALUE OF IMATINIB IN PREVENTION OF COVID-19 IN AGED PATIENTS.
    Medical condition: Aged patients at risk of COVID-19 infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10051905 Coronavirus infection LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-007835-16 Sponsor Protocol Number: MRZ 92579/TI/3001 Start Date*: 2009-03-19
    Sponsor Name:Merz Pharmaceuticals GmbH
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Clinical Evaluation of the Efficacy, Safety and Tolerability of Neramexane in Patients with Subjective Tinnitus
    Medical condition: Efficacy, Safety and Tolerabilty of Neramexane in Patients with subjective Tinnitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10042398 Subjective tinnitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) GB (Completed) PT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-001169-32 Sponsor Protocol Number: CA180-035 Start Date*: 2005-11-16
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized Two-Arm, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 70 mg Twice Daily or 140 mg Once Daily in Subjects with Chronic Myeloid Leukemia in Acce...
    Medical condition: Subjects with Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP) or in Myeloid (My) or Lymphoid (Ly) Blast Phase (BP) or with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) HU (Completed) DK (Completed) IE (Completed) CZ (Completed) FI (Completed) ES (Completed) IT (Completed) BE (Completed) DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2019-000220-18 Sponsor Protocol Number: SHR-1210-III-310 Start Date*: 2020-09-17
    Sponsor Name:Jiangsu Hengrui Pharmaceuticals Co., Ltd.
    Full Title: A Randomized, Open-Label, International, Multi-Center, Phase 3 Clinical Study of PD-1 Antibody SHR-1210 Plus Apatinib (Rivoceranib) Mesylate Versus Sorafenib as First-Line Therapy in Subjects with ...
    Medical condition: Advanced Hepatocellular Carcinoma (HCC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) ES (Ongoing) BE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-000497-50 Sponsor Protocol Number: 11051 Start Date*: 2005-11-21
    Sponsor Name:H. Lundbeck A/S
    Full Title: An open-label safety study of bifeprunox investigating flexible doses of 20, 30, or 40mg/day in patients with schizophrenia who have completed studies 10206 or 10265
    Medical condition: male and female patients with schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    6.1 10039626 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-001805-34 Sponsor Protocol Number: CSTI571I1203 Start Date*: 2017-08-15
    Sponsor Name:Novartis Pharma K.K
    Full Title: Phase II Study of Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia
    Medical condition: Philadelphia Chromosome Positive Acute Lymphocytic Leukemia (Ph+ALL)
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-019568-35 Sponsor Protocol Number: OPTIM IMATINIB Start Date*: 2010-06-14
    Sponsor Name:CH VERSAILLES
    Full Title: A prospective randomized phase II study evaluating the monitoring of imatinib mesylate (Gliveec®) plasmatic through level in patients newly diagnosed with chronic phase chronic myelogenous leukaemi...
    Medical condition: Chronic Phase Chronic myelogenous leukemia (CP CML)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-001860-27 Sponsor Protocol Number: A6181036 Start Date*: 2007-09-12
    Sponsor Name:Pfizer Limited
    Full Title: A TREATMENT PROTOCOL FOR PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR WHO ARE INELIGIBLE FOR PARTICIPATION IN OTHER SU011248 PROTOCOLS AND ARE REFRACTORY TO OR INTOLERANT OF IMATINIB MESYLATE
    Medical condition: Patients with Gastrointestinal Stromal Tumor who are Refractory to Standard Therapy and May Derive Benefit for Treatment with SU011248
    Disease: Version SOC Term Classification Code Term Level
    7.1 10062427 LLY
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SK (Completed) HU (Completed) FI (Completed) DK (Completed) AT (Prematurely Ended) SE (Completed) ES (Prematurely Ended) GR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-001810-16 Sponsor Protocol Number: 62024 Start Date*: 2004-11-25
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Intermediate and high risk localized, completely resected, gastrointestinal stromal tumors (GIST) expressing KIT receptor: a controlled randomized trial on adjuvant Imatinib mesylate (Glivec) versu...
    Medical condition: Gastrointestinal stromal tumors (GIST) are mesenchymal neoplasms usually arising from the gastrointestinal wall. Pathologically,they present with spindle cells in most cases. Immunohistochemically...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10051066 Gastrointestinal stromal tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) GB (Completed) ES (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 22:42:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA